A new research study advocates the hope of long-term remission of multiple sclerosis.
Five years after receiving the treatment, known as high-dose immunosuppressive therapy and hematopoietic cell transplant (HDIT/HCT) and transplantation of an individual’s own stem cells, 69 percent of participants continued to exist with no advancement of impairment, deterioration of MS symptoms or new brain lesions.
The National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health, subsidized the trial known as HALT-MS.
According to NIAID Director Anthony Fauci, M.D. the results of the trial indicate the one-time healing with HDIT/HCT may be to a large extent more successful than long-term treatment with existing medication.
For example, five years after HDIT/HCT, most trial participants continued to be in remission and their multiple sclerosis had become stable. Some even demonstrated signs of improvements, such as improvements in mobility or other physical abilities.
Motor and speech difficulties, weakness, fatigue and chronic pain are among the symptoms the disease may demonstrate. Taking part in the study were volunteers aged 26 to 52 with relapsing-remitting MS.
The researchers published the initial three-year results in December 2014 and the five-year results were published online in the medical journal of the American Academy of Neurology February 1.
A Voorhees, New Jersey-based practicing neurologist and specialist in psychiatry Dr. Shiva Gopal Vasishta is a member of the group practice Eastern Neurodiagnostic Associates.
Neurologists are doctors who diagnose, identify and care for sicknesses of the nervous system including the brain, nerves and spinal cord.
Dr. Shiva Gopal Vasishta received his medical degree from Government Medical College Nagpur and completed his residency at Boston City Hospital.
Affiliated with Kennedy Health System Cherry Hill Campus, Dr. Shiva Gopal Vasishta has practiced for forty years. Dr. Shiva Gopal Vasishta is board certified in neurology.